Scott Willoughby
General Counsel bei SANGAMO THERAPEUTICS, INC.
Vermögen: 402 095 $ am 30.04.2024
Profil
Scott Willoughby is currently the Secretary, Senior VP & General Counsel at Sangamo Therapeutics, Inc. He previously worked as the Vice President-Deputy General Counsel & Head-Law at Achaogen, Inc. He received his undergraduate and graduate degrees from the University of California, Berkeley.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 25.02.2024 | 799 393 ( 0,39% ) | 402 095 $ | 30.04.2024 |
Aktive Positionen von Scott Willoughby
| Unternehmen | Position | Beginn |
|---|---|---|
| SANGAMO THERAPEUTICS, INC. | General Counsel | - |
Ehemalige bekannte Positionen von Scott Willoughby
| Unternehmen | Position | Ende |
|---|---|---|
| ACHAOGEN | General Counsel | - |
Ausbildung von Scott Willoughby
| University of California, Berkeley | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SANGAMO THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Achaogen, Inc.
 Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
